Relationship between the prognostic and predictive value of the intrinsic subtypes and a validated gene profile predictive of loco-regional control and benefit from post-mastectomy radiotherapy in patients with high-risk breast cancer

Acta Oncologica

Volumn 53, Issue 10, 2014, Pages 1337-1346

  Tramm, Trine ^a   Kyndi, Marianne ^a   Myhre, Simen ^b,c   Nord, Silje ^b   Alsner, Jan ^a   Sorensen, Flemming Brandt ^d   Sorlie, Therese ^b,c   Overgaard, Jens ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d LILLEBAELT HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; FORMALDEHYDE; KI 67 ANTIGEN; METHOTREXATE; PARAFFIN; PROGESTERONE RECEPTOR; TAMOXIFEN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

AGED; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER CONTROL; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER TISSUE; FEMALE; FROZEN SECTION; GENE EXPRESSION PROFILING; GENETIC HETEROGENEITY; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOCAL RECURRENCE FREE SURVIVAL; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MASTECTOMY; MICROARRAY ANALYSIS; OUTCOME ASSESSMENT; POSTOPERATIVE CARE; PREDICTIVE VALUE; RECURRENCE RISK; RISK ASSESSMENT; TISSUE FIXATION; TRIPLE NEGATIVE BREAST CANCER; BREAST NEOPLASMS; CHEMISTRY; CHEMORADIOTHERAPY; CONTROLLED STUDY; GENETICS; LYMPH NODE DISSECTION; PATHOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMORADIOTHERAPY; CYCLOPHOSPHAMIDE; ERBB RECEPTORS; FEMALE; FLUOROURACIL; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LYMPH NODE EXCISION; MASTECTOMY; METHOTREXATE; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAMOXIFEN;

EID: 84909611944     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2014.925580     Document Type: Article

References (25)

1. EBCTCG Early Breast Cancer Trialists'Collaborative Group. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: Meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet Epub 2014 Mar 19.
2. Grantzau T, Mellemkjaer L, Overgaard J. Second primary cancers after adjuvant radiotherapy in early breast cancer patients: A national population based study under the Danish Breast Cancer Cooperative Group (DBCG). Radiother Oncol 2013; 106: 42-9.
3. Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Bronnum D, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 2013; 368: 987-98.
4. Overgaard M, Jensen MB, Overgaard J, Hansen PS, Rose C, Andersson M, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 1999; 353: 1641-8.
5. Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997; 337: 949-55.
6. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-26.
7. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-6.
8. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003; 362: 362-9.
9. Tramm T, Mohammed H, Myhre S, Kyndi M, Alsner J, Børresen-Dale A, et al. Development and validation of a gene profile predicting benefit of post-mastectomy radiotherapy in high risk breast cancer patients: A study of gene expression in the DBCG82bc cohort. EJC Supplements 2013; 11:Abstract 1856
10. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-52.
11. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-74.
12. Sørlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100: 8418-23.
13. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009; 27: 1160-7.
14. Haibe-Kains B, Schroeder M, Bontempi G, Sotiriou C, Quackenbush J. genefu: Relevant functions for gene expression analysis, especially in breast cancer. R package, version 1.14.0.
15. Wu SG, He ZY, Li Q, Li FY, Lin Q, Lin HX, et al. Predictive value of breast cancer molecular subtypes in Chinese patients with four or more positive nodes after postmastectomy radiotherapy. Breast 2012; 21: 657-61.
16. Kyndi M, Sørensen FB, Knudsen H, Overgaard M, Nielsen HM, Overgaard J, et al. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: The Danish Breast Cancer Cooperative Group. J Clin Oncol 2008; 26: 1419-26.
17. Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 2010; 28: 1684-91.
18. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10: 5367-74.
19. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009; 101: 736-50.
20. Weigelt B, Mackay A, A'hern R, Natrajan R, Tan DS, Dowsett M, et al. Breast cancer molecular profiling with single sample predictors: A retrospective analysis. Lancet Oncol 2010; 11: 339-49.
21. Laurberg T, Tramm T, Gelmon K, Alsner J, Leung S, Sørlie T, et al. In two independent randomized trials young high risk breast cancer patients with luminal A tumors had benefit from postmastectomy radiation therapy. EJC Supplements 2013; 11:Abstract 1850.
22. Myhre S, Mohammed H, Tramm T, Alsner J, Finak G, Park M, et al. In silico ascription of gene expression differences to tumor and stromal cells in a model to study impact on breast cancer outcome. PLoS One 2010; 5: e14002.
23. Kyndi M, Sorensen FB, Knudsen H, Overgaard M, Nielsen HM, Andersen J, et al. Tissue microarrays compared with whole sections and biochemical analyses. A subgroup analysis of DBCG 82 b & c. Acta Oncol 2008; 47: 591-9.
24. Bastien RR, Rodriguez-Lescure A, Ebbert MT, Prat A, Munarriz B, Rowe L, et al. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. BMC Med Genomics 2012; 5: 44.
25. Lusa L, McShane LM, Reid JF, De Cecco L, Ambrogi F, Biganzoli E, et al. Challenges in projecting clustering results across gene expression-profiling datasets. J Natl Cancer Inst 2007; 99: 1715-23.